Navigation Links
Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos's Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
Date:5/3/2012

DURHAM, N.C., May 3, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that study results demonstrated that analytical treatment interruption to assess the antiviral activity of Argos's Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004, is an acceptable strategy for at least 16 weeks. Study results were published in the Journal of Medical Virology (84:885–889, 2012).

"Establishing the safety of analytical treatment interruptions of at least 16 weeks is an important step forward in assessing the impact of immunotherapy on viral load control," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "Therapeutic vaccines such as AGS-004 have the potential to decrease long-term antiretroviral therapy which has limitations such as drug toxicity, the risk of developing resistance and others. We look forward to advancing our Phase 2b trial of AGS-004 to further demonstrate its efficacy and safety for the treatment of HIV patients."

The potential risks of short-term interruption of antiretroviral therapy in the AGS-004-001 study were assessed in a retrospective subgroup study analyzing data from patients in the strategies for management of anti-retroviral therapy (SMART) study with matched eligibility criteria. The subgroup analysis included 440 of 2,720 on the drug conservation (DC) arm and 436 of 2,752 on the viral suppression (VS) arm that matched the AGS-004-001 inclusion criteria and were used in the SMART subgroup analysis. In the first 16 weeks following randomization into the SMART study there were no deaths in either subgroup.  There were two AIDS-related events in the DC subgroup and one in the VS subgroup, making the overall risk of AIDS related events two per 100 person years (0.005%) and one per 100 person years (0.002%) in the two subgroups, respectively.  There were
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 2011 A new report in the March issue of ... beat brand names when it comes to safety, efficacy, and ... drug programs offering these drugs at prices as low as ... Walgreens, and Walmart have been steadily expanding their discount programs, ...
... JumpStart Ventures , the non-profit that invests in ... Ohio, and Cleveland Clinic , announced a ... Inc. The Cleveland-based company is developing a topical ... formation in wounds. (Logo: http://photos.prnewswire.com/prnh/20060209/CLJUMPSTARTLOGO) ...
Cached Medicine Technology:Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month 2Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month 3Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month 4JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics 2JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics 3JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics 4
(Date:7/9/2014)... researchers have uncovered mutations in a cell-signaling pathway that ... may expand treatments for patients because drugs targeting some ... in clinical trials. , Reporting July 9 in ... including researchers at Washington University School of Medicine in ... tumors from 230 patients with lung adenocarcinoma. , "This ...
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
(Date:7/9/2014)... personal and subjective, the human brain turns them ... across different senses, situations and even people, reports ... Anderson. , "We discovered that fine-grained patterns of ... of the brain associated with emotional processing, act ... subjective feeling," says Anderson, associate professor of human ...
(Date:7/9/2014)... There has been a sharp increase in the number ... MyChart, the online, interactive service that allows patients to ... providers, schedule appointments, and renew prescriptions. , Over a ... MyChart each year increased five-fold, while the number ... according to a study by Dr. David Gerber ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3
... DavisPTnetwork™, a new social networking Web site, at the APTA ... online physical therapy continuing education courses (contact hours and CEUs), ... ... Philadelphia, PA (PRWEB) March 23, 2009 -- F.A. Davis is ...
... Digital,s unique PC Network software with the advanced SharkNet Duplicator series ... a given network onto a duplicator. , ... Los ... the availability of their latest innovation; the network connectable standalone duplicator ...
... Tuberculosis Day HARRISBURG, Pa., March 23 State Health ... public awareness of tuberculosis, or TB, and the importance ... disease. "In 2008, we saw an increase in the ... more cases resistant to medication, which makes the disease ...
... Nickolas Hooks of Charleston, SC, will travel ... 31, 2009 to meet with congressional leaders and gain ... research toward a cure for epilepsy.Hooks, 15, is one ... in Kids Speak Up! , a national program ...
... In light of the recent recall of eggs ... safety expert Jeff Nelken is strongly advising Americans, especially ... take precautions when eating eggs at home or in ... potentially one of the most dangerous foods in terms ...
... PEMBROKE, Bermuda, March 23 Darwin National,Assurance Company, ... Ltd (NYSE: AWH ), today announced ... moderate a panel at the PLUS Medical,Symposium held ... The panel, titled "Do,You Know Where Your Tissue/Organ/Medical ...
Cached Medicine News:Health News:New Online Network Features Continuing Education Courses for Physical Therapists 2Health News:Vinpower Digital Introduces the Industry's First Standalone Networkable Duplication Tower 2Health News:Vinpower Digital Introduces the Industry's First Standalone Networkable Duplication Tower 3Health News:Pennsylvania Sees Increase in Tuberculosis, Emphasizing Need for Awareness 2Health News:South Carolina Youth Shares Epilepsy Message on Capitol Hill 2Health News:Food Safety Expert Offers Tips to Be Safe in Wake of Costco & Safeway Egg Recall 2Health News:Darwin to Moderate Panel at Plus Medical Symposium 2Health News:Darwin to Moderate Panel at Plus Medical Symposium 3
... indoor positioning supports patient safety by ... the right patients are in the ... Respond to the exact patient location ... monitor alarms. Measure patient flow times ...
... are preominantly used for routine blood collection. ... of the needle protective cap simplifies visual ... example, yellow symbolises the needle dimension 20 ... mm) and black 22 G (0.70 mm). ...
DiaMed-ID Micro Typing System...
Bio-Rad's ScanGel® cards for ABO reverse grouping, antibody screening and crossmatching include - ScanGel Neutral, ScanGel Coombs, Anti-IgG, -C3d (AHG), ScanGel Coombs + Neutral, ScanGel Anti-Ig...
Medicine Products: